Literature DB >> 27913504

Primary central nervous system lymphoma.

Tracy T Batchelor1.   

Abstract

Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the brain, leptomeninges, eyes, or spinal cord. The majority of PCNSL cases occur in the immunocompetent host, the focus of this review. The prognosis of PCNSL is inferior to that of other NHL subtypes including other organ-specific subtypes of extranodal NHL. The 5- and 10-year survival proportions for PCNSL are 29.3% and 21.6%, respectively. The diagnosis and management of PCNSL differs from that of other primary brain cancers and NHL in other parts of the body.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Year:  2016        PMID： 27913504      PMCID： PMC6142465          DOI： 10.1182/asheducation-2016.1.379

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  42 in total

1.  Prophylactic intrathecal chemotherapy in primary CNS lymphoma.

Authors:  Monica Sierra Del Rio; Damien Ricard; Caroline Houillier; Soledad Navarro; Alberto Gonzalez-Aguilar; Ahmed Idbaih; Gentian Kaloshi; Soufiane Elhallani; Antonio Omuro; Sylvain Choquet; Carole Soussain; Khé Hoang-Xuan
Journal:  J Neurooncol       Date:  2011-07-08       Impact factor: 4.130

2.  Surgery for primary CNS lymphoma? Challenging a paradigm.

Authors:  Michael Weller; Peter Martus; Patrick Roth; Eckhard Thiel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2012-09-14       Impact factor: 12.300

3.  Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

Authors:  Paul L Nguyen; Arnab Chakravarti; Dianne M Finkelstein; Fred H Hochberg; Tracy T Batchelor; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

4.  Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Authors:  Antonio Omuro; Olivier Chinot; Luc Taillandier; Hervé Ghesquieres; Carole Soussain; Vincent Delwail; Thierry Lamy; Rémy Gressin; Sylvain Choquet; Pierre Soubeyran; Aymeri Huchet; Alexandra Benouaich-Amiel; Sophie Lebouvier-Sadot; Emmanuel Gyan; Valérie Touitou; Maryline Barrié; Monica Sierra del Rio; Alberto Gonzalez-Aguilar; Caroline Houillier; Daniel Delgadillo; Lucette Lacomblez; Marie Laure Tanguy; Khê Hoang-Xuan
Journal:  Lancet Haematol       Date:  2015-06-03       Impact factor: 18.959

5.  Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.

Authors:  Annika Juergens; Hendrik Pels; Sabine Rogowski; Klaus Fliessbach; Axel Glasmacher; Andreas Engert; Marcel Reiser; Volker Diehl; Marlies Vogt-Schaden; Gerlinde Egerer; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Udo Bode; Ulrich Herrlinger; Michael Linnebank; Martina Deckert; Rolf Fimmers; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

Review 6.  First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Authors:  B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

7.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Authors:  Sophie Langner-Lemercier; Caroline Houillier; Carole Soussain; Hervé Ghesquières; Olivier Chinot; Luc Taillandier; Pierre Soubeyran; Thierry Lamy; Franck Morschhauser; Alexandra Benouaich-Amiel; Guido Ahle; Marie-Pierre Moles-Moreau; Cécile Moluçon-Chabrot; Pascal Bourquard; Ghandi Damaj; Fabrice Jardin; Delphine Larrieu; Emmanuel Gyan; Remy Gressin; Arnaud Jaccard; Sylvain Choquet; Annie Brion; Olivier Casasnovas; Philippe Colin; Oumedaly Reman; Adrian Tempescul; Jean-Pierre Marolleau; Michel Fabbro; Florian Naudet; Khê Hoang-Xuan; Roch Houot
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

Review 8.  Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.

Authors:  Rose Lai; Lauren E Abrey; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

Review 9.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

10.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more
  9 in total

1.  Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.

Authors:  Andrés J M Ferreri; Teresa Calimeri; Maurilio Ponzoni; Flavio Curnis; Gian Marco Conte; Eloise Scarano; Eltjona Rrapaj; Daniela De Lorenzo; Dario Cattaneo; Federico Fallanca; Alessandro Nonis; Marco Foppoli; Paolo Lopedote; Giovanni Citterio; Letterio S Politi; Marianna Sassone; Piera Angelillo; Elena Guggiari; Sara Steffanoni; Vittoria Tarantino; Fabio Ciceri; Claudio Bordignon; Nicoletta Anzalone; Angelo Corti
Journal:  Blood Adv       Date:  2020-08-11

2.  Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.

Authors:  Feili Chen; Diwen Pang; Hanguo Guo; Qiuxiang Ou; Xue Wu; Xinmiao Jiang; Xiaojuan Wei; Sichu Liu; Ling Huang; Zhanli Liang; Dong Zhou; Wenyu Li
Journal:  Cancer Med       Date:  2020-10-17       Impact factor: 4.452

3.  R-IDARAM treatment in central nervous system lymphomas: A single-center experience and review of the literature.

Authors:  Senem Maral; Murat Albayrak; Cigdem Pala; Abdulkerim Yıldız; Hacer B Ozturk; Osman Sahin
Journal:  Avicenna J Med       Date:  2020-10-13

4.  Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Jing Liu; Jiayuan Guo; Xuefei Sun; Yuanbo Liu; Chunji Gao
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

5.  Case series on patients with primary central nervous system lymphoma: From clinical presentations to outcomes.

Authors:  Kazem Anvari; James S Welsh; Fatemeh Molaie
Journal:  Clin Case Rep       Date:  2022-02-21

Review 6.  Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.

Authors:  Angelo Corti; Teresa Calimeri; Flavio Curnis; Andres J M Ferreri
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525

7.  Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.

Authors:  Yangying Zhou; Wei Liu; Zhijie Xu; Hong Zhu; Desheng Xiao; Weiping Su; Ruolan Zeng; Yuhua Feng; Yumei Duan; Jianhua Zhou; Meizuo Zhong
Journal:  Neoplasia       Date:  2018-09-15       Impact factor: 5.715

8.  Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.

Authors:  Yi-Xia Wang; Yan Huang; Xiao-Ping Xu; Bo-Bin Chen; Zhi-Guang Lin; Yan Ma; Tian-Ling Ding; Qian Wang
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

9.  A Case Report on Primary Central Nervous System Lymphoma in Immunocompetent Individual.

Authors:  Shobha Mandal; Sunil Shah; Sumit Gami; Barun Ray; Joyson Poulose
Journal:  Cureus       Date:  2021-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.